Skip to main contentPsst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveFree Webinar — Wednesday, November 11 at 2:00 PM ET

Register Free →

NIMHD Division of Intramural Research Population Health and Clinical Research — Small Business Sources Sought

Open
75N94027R00005Federal

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

General Info

NAICS

541715 - Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

Place of Performance

MD, USA

Set-Aside

NONE

Documents

2
DOCX
DOCX

AI Contract Breakdown

Uniform Contract Format

Contract not broken down yet

CLEATUS splits the solicitation into Uniform Contract Format (UCF) sections: scope, pricing, deliverables, and evaluation criteria.

Timeline

PhaseSources Sought
Posted

Sources Sought

Response Deadline

Submission deadline

Response Deadline

Ready to pursue this opportunity?

Get full access to track this contract, build proposals with AI assistance, and manage your pipeline.

Organization & Contact Information

Show more
AgencyDepartment Of Health And Human Services → National Institutes Of Health Olao
Contacts2 people available
OfficeBETHESDA, MD, 20892, USA
Office AddressBETHESDA, MD, 20892, USA
Contacts

Full Description

Show more

Synopsis:


This is a Small Business Sources Sought notice. This is NOT a solicitation for proposals, proposal abstracts, or quotations.


The purpose of this notice is to obtain information regarding: (1) the availability and capability of qualified small business sources to perform a potential requirement; (2) whether they are small businesses; 8(a) small businesses, service-disabled veteran-owned small businesses; veteran-owned small businesses; women-owned small businesses; HUBZone small businesses; or small disadvantaged businesses; and (3) their size classification relative to the North American Industry Classification system (NAICS) code for the potential acquisition. Your responses to the information requested will assist the government in determining the appropriate acquisition method, including whether a small business set aside is possible. An organization that is not considered a small business under the applicable NAICS code should not submit a response to this notice. The requirement is assigned a code of 541715 in the North American Industry Classification System (NAICS), and the small business size standard for such requirements is 1,000 employees or less.


This notice is issued for market research purposes to assess potential small business sources, industry practices, and the availability of commercial services. The Government has not made a final determination regarding acquisition strategy, contract type, commerciality, or small business set-aside status. Respondents should identify whether they can perform the requirement as a prime contractor, including through existing teaming arrangements or qualified subcontractors, and distinguish their own capabilities from those of proposed team members.


Background:


The National Institute on Minority Health and Health Disparities (NIMHD) conducts and supports research and training programs to advance knowledge and understanding of health disparities, identify mechanisms to improve minority health and reduce health disparities, and develop effective interventions in community and clinical settings. 


NIMHD is the lead organization at the National Institutes of Health (NIH) for planning, reviewing, coordinating, and evaluating minority health and health disparities research activities. NIMHD also promotes workforce development, supports research capacity at less-resourced institutions that train students in research careers, serves populations experiencing health disparities, supports participation in clinical research, and promotes information dissemination through regular communications, public education outreach, and scientific presentations. 


The President’s Executive Order (EO) 14212 Establishing the President’s Make America Healthy Again Commission aims to improve the health of Americans. As described in the EO, escalating burden of chronic diseases poses significant challenges in the United States. These conditions contribute to rising health costs, reduced workforce productivity, and stagnant life expectancies across the country, both in adults and children.  


NIH defines a health disparity as a measurable difference in health that exists between specific population groups. This is a rigorously derived and data-driven determination operationalized by quantifiable metrics, rather than a statement of attribution. It is a scientific starting point that identifies where health outcomes diverge, not a predetermined conclusion about why. Scientific investigations to identify or understand the root causes are separate and distinct scientific questions, which are necessarily multifaceted and complex. NIH funded research is interested in those health disparities that are modifiable or actionable to improve the health of all population groups. 


Health disparities may be observed in the risks, prevalence, or problems resulting from specific behaviors, as well as the incidence, prevalence, and mortality from conditions, diseases, and/or disorders. 


To fulfill the NIH mission of seeking fundamental knowledge about the nature and behaviors of individuals as living systems, and the statutory purpose of NIMHD, to conduct research to understand and reduce health disparities, NIMHD Division of Intramural Research (DIR) conducts population health research to understand how health outcomes vary across populations, identify multilevel modifiable factors that drive these disparities, and develop, test, and evaluate clinical and population-based interventions to reduce these disparities. 


NIMHD DIR requires contractor assistance to provide R&D social and behavioral sciences research services to support NIMHD DIR in conducting population health and clinical research to understand and reduce health disparities in the United States.


The Government anticipates that individual task orders may involve differing research designs, study populations, sites, durations, and levels of complexity. Interested firms should explain their ability to mobilize qualified personnel and research resources for multiple concurrent studies as requirements arise.


NIMHD is seeking small businesses capable of designing, conducting and overseeing the clinical, scientific, and technical aspects of investigations into health disparities across populations, to identify modifiable risk and protective factors associated with these disparities, and develop and test interventions to reduce these disparities. Study designs to be used may include, but are not limited to:  


  • Population-based cross-sectional surveys; 

  • Epidemiological studies (e.g., longitudinal cohort study, case-control studies);  

  • Clinical trials; 

  • Community-based intervention studies;  

  • Simulation modeling; and  

  • Qualitative research methods (e.g., direct observations, in-depth interviews, focus groups discussions).  

Independently and not as an agent of the Government, the Contractor shall furnish all necessary services, qualified personnel, material, equipment, and facilities not otherwise provided by the Government to successfully perform the requirements stated below. Specifically, the Contractor shall, as required by individual task orders, perform the following technical requirements summarized below that also are included in the attached Draft Statement of Work (SOW), including but not limited to:


  1. Provide personnel, facilities, and other services necessary to maintain and coordinate multiple health disparities research studies funded through task orders under this Indefinite Delivery, Indefinite Quantity (IDIQ) contract.
  2. Provide overall project management and coordination of activities performed under individual task orders, including development and maintenance of project plans, schedules, milestones, coordination of participating research sites and subcontractors, monitoring of performance, identification and resolution of project risks and issues, and preparation of progress reports as specified in the applicable task order.
  3. Conduct research studies through qualified organizations, as specified in individual task orders, and receiving consent from the Contracting Officer’s Representative (COR) and Contracting Officer (CO). This includes (but is not limited to) implementation of protocols; population health and clinical research site monitoring; regulatory compliance assurance; and analyses of data from clinical, laboratory, population and epidemiologic studies.
  4. Provide and manage participating population health research and clinical trial sites, investigators, laboratories, and other research resources necessary to conduct studies, directly or through qualified subcontractors.
  5. The Contractor shall draft, negotiate, execute, administer, monitor, renew and/or modify as necessary, subject to subcontractor's satisfactory past performance, and with the consent of the CO, subcontracts with domestic population health studies, clinical research sites and laboratories, and provide support for these population health studies, clinical research site and laboratories. The Contractor shall assume responsibility for population health and clinical sites, including site readiness to start new research studies. This includes the establishment of new subcontract agreements for these sites (including laboratories), data management, and other operations and functions. As existing protocols close, the Contractor shall assume responsibility for any new protocols at these sites.
  6. Recruit and retain numbers of potential research subjects sufficient for the timely completion of all protocols.
  7. Provide United States based investigators in the United States with expertise in the population health and clinical care, to conduct protocols specified through individual task orders.
  8. Provide professional and technical staff adequate to provide scientific and administrative coordination of multiple population health and clinical health disparities research studies. These staff shall include, but are not limited to, qualified medical, nursing, and neuropsychologic staff, study coordinators, personnel for participant identification, recruitment, study conduct, and retention, pharmacists, and laboratory technicians.
  9. Ensure sites have access to populations of interest, laboratory facilities with the capability to perform clinical research specified in task orders.
  10. Identify and engage community organizations, community leaders, health care providers, and other relevant stakeholders; establish and support community advisory boards, community coalitions, or other partnerships; conduct community needs and readiness assessments; and facilitate community participation in research planning, implementation, and dissemination of findings.
  11. Develop and implement quantitative and qualitative data collection methods, including surveys, interviews, focus groups, direct observations, and other methods appropriate to the research protocol. The Contractor shall manage, analyze, and report data collected through these methods, as required by individual task orders.
  12. Provide facilities and equipment adequate to conduct population health, inpatient and outpatient clinical research studies. Equipment purchases must be approved by the COR and CO.
  13. Ensure that sites have (through lease or direct provision, if required) electronic information systems compliant with the Federal Information Security Modernization Act (FISMA), necessary specialized equipment (including hardware and software) for sites to electronically communicate with the Contractor, subcontractors, and NIMHD DIR as required, for processing and storage of biospecimens (e.g., ultralow temperature freezer, specialized shipping materials and training for shipment of biohazardous materials and dangerous goods, and for receipt, storage, monitoring, and dispensing of investigational drugs).
  14. Obtain access for research protocol review and approval (or exemption) to a standing Institutional Review Board (IRB) and ensure that each institution conducting population health and clinical research studies has a current, approved Federal-Wide Assurance Number on file with the Office for Human Research Protections (OHRP).
  15. Ensure that all the staff at each site participating in the design or conduct of population health and clinical research involving human subjects, complete and maintain education on the human research protections.
  16. Ensure that when appropriate, population health and clinical research sites have a community advisory board (CAB) constituted with members of the local community that can provide community perspective and advice for science in the community where the population health and clinical research is located and that provides community input.
  17. The Contractor shall provide services to ensure regulatory compliance for research activities including subcontracted sites' performance. More specifically:
    1. Ensure site access to a communications system in compliance with U.S. Food and Drug Administration (FDA) requirements for the submission of Adverse Experience Reports (AERs) by Subcontractors to the Contractor for transmission as required to the COR as required. Monitor the accuracy of adverse experience reporting through regular summary reports for submission to the COR. Draft safety reports as required by the FDA for selected studies for COR Submission.
    2. Develop, implement, and monitor plans for acquisition, distribution, dispensing, handling, administration, and accountability of study interventions (pharmaceutical and non-pharmaceutical), in compliance with applicable Federal, state, and local regulations.
    3. Provide site monitoring for quality assurance of research conducted at all clinical and laboratory sites, as designated by the COR. Monitoring schedules shall be approved by and results reported to the COR with a copy to the CO and shall include assurance of compliance with FDA record keeping and reporting requirements (21 CFR 50 and 56; 21 CFR 312.50, Subpart D), accuracy and completeness of case report forms, source documentation, and other research records, and periodic record auditing and documentation by the staff of the subcontracted centers. Each site shall be visited a minimum of 2-3 times annually. Provide staff with laboratory expertise and assist in monitoring clinical trials site laboratory quality with the COR and NIMHD Quality Assurance (QA) programs.
    4. Meet with the NIMHD program and contracting staff to review annual site performance and monitoring reports for participating population health and clinical research sites.
  18. The Contractor shall provide population health, clinical and statistical analysis and reports. More specifically:
    1. Provide scientific, technical, and administrative support for the development, implementation, and analysis of the specified research, including considerations of experimental design, sample size calculation, and interim and final primary and secondary analyses specified by study protocols, as requested by the COR.
    2. Establish data elements to be recorded by the protocol research records, as requested by the COR and in conjunction with the protocol development team for each specific research project. Develop study forms for standardized collection of data items. Develop documentation and coding for computerization of data for retrieval, analysis, and reporting.
    3. Provide for timely and accurate data collection and submission, data entry, data quality assurance, retrieval of source documentation, and generation of data and safety monitoring reports.
    4. Provide training for staff of population health, clinical and laboratory sites in data management procedures.
    5. Provide data input, editing, electronic data storage, database management, data retrieval, and statistical analysis using well-documented database management and statistical computer software programs.
    6. Develop methodology, perform analyses, and provide results from meta-analyses of selected data sets derived from population health and clinical research studies that focus on health disparities.
    7. Provide data analysis and results. More specifically:
      • Perform statistical analyses of study data to test study hypotheses and evaluate potential confounding variables and/or covariates, as requested by the COR. Data analytic techniques needed include approaches to analyzing multiple measurements of biologic variables over time within participants and between participant groups, with consideration for normal changes in these variables with demographics.
      • Provide for biweekly to monthly communication, as needed, of analytic progress and results through routine meetings (the majority to be virtually) with COR or designees and periodic generation of reports. The Project Manager shall attend all meetings. The Epidemiologist, Statistician, and Senior Systems Analyst shall attend these meetings on an as needed basis dependent upon the PI’s request.
      • Provide programming and statistical support adequate for the timely generation of additional analyses requested by the COR.
    8. Provide electronic data transmission between the Contractor, population health, clinical and laboratory sites, and NIMHD DIR using currently specified communications software and equipment.
    9. Provide for electronic mail transmission between the Contractor, population health, clinical and laboratory sites, and NIMHD DIR using commercially available communications software and equipment.
    10. Provide protocol development services and assistance.
  19. The Contractor shall provide services for the implementation and monitoring of multiple population health and clinical research studies. More specifically:
    1. Develop, initiate and coordinate implementation and oversight of protocols at all participating population health, clinical and laboratory sites designed by the COR and approved by the CO. Ensure compliance by sites with all requirements for protocol implementation, including IRB review and approval prior to protocol initiation, participant consent, and confidentiality requirements, and Federal bioresearch regulations and requirements for security and confidentiality of research records, and that each relevant population health and clinical research site staff member completes and maintains human research protection and Good Clinical Practice training, when appropriate.
    2. Draft, negotiate, execute, administer, monitor, renew and/or modify as necessary with approval by CO a site-specific, protocol-specific budget for each protocol to be conducted by population health, clinical and laboratory sites, based on the anticipated number of participants to be enrolled.
    3. Provide training for staff of clinical and laboratory centers in procedures for implementation and conduct of specific protocols. Retraining may be required to be performed as necessary.
    4. Provide training in and ensure the fulfillment and maintenance of standards for Good Clinical Practices (GCP) and Good Clinical Laboratory Practices (GCLP) across population health and clinical research sites and staff, whenever appropriate.
    5. Ensure timely development and execution of material transfer agreements (MTAs) and data transfer agreements (DTAs) between the sponsor(s) and population health and clinical research sites.
  20. The Contractor shall provide services for the development and review of research activities. More specifically:
    1. For specific new protocol topics identified by the COR, identify a protocol development team consisting of Contractor staff, NIH staff, subcontractors, and/or consultants. Provide support for the planning and conduct of protocol development team meetings. Submit at the initial meeting a protocol development plan for COR review and approval, addressing regulatory issues, data collection forms development, drug distribution plan, protocol timeline, and participating sites. Develop a protocol document including background, objectives and endpoints, design, patient numbers, source, management, and selection, study agents or other interventions, clinical and laboratory monitoring, laboratory services, toxicity management, adverse experience reporting, evaluation of response, statistical considerations, data collection and monitoring, human subjects’ considerations, biohazard containment, and data and safety reviews. Review, edit, and rewrite draft protocols based on COR’s review. Prepare and maintain the necessary documentation for application submissions in compliance with FDA requirements. Upon completion of a final protocol, renegotiate subcontractor budgets with the approval of the CO and implement the new protocol at participating sites.
    2. For ongoing protocols, provide, at the request of the COR, support for the planning and conduct of meetings of protocol committees and subcommittees, data and safety monitoring boards, and investigators.
    3. Provide administrative, technical, and logistical support at the request of the COR and with approval of the CO as needed for interaction and collaboration of the Subcontractors with other institutes, agencies, and organizations conducting activities relevant to health disparities research.
    4. Support the identification, development, implementation, and evaluation of interventions to improve health outcomes and reduce health disparities, including assessment of feasibility, acceptability, effectiveness, and potential impact.
  21. Provide consultants with specialized expertise related to population health and clinical research especially related to health disparities, as requested by NIMHD DIR.
  22. Plan, organize, and coordinate meetings involving internal and outside experts. This meeting will be an important venue to discuss important and complex scientific issues related to research protocols and emerging research priorities.
  23. Provide support services for ongoing population health and clinical research studies, which include, but are not limited to, the following: site monitoring, subcontract management and invoicing, protocol management, oversight of data management and data analysis, study agent procurement, team meetings, regulatory compliance assurance, site activation and protocol registration, safety monitoring, committee management, data management services, oversight of central and site laboratories and pharmacies, protocol team support, FISMA compliance and IT security, laboratory equipment support, and training of site personnel, to support this effort.
  24. Provide Core infrastructure support for ongoing population health and clinical research at the sites, including but not limited to the following: maintenance of IRB/EC regulatory reporting, subject recruitment and follow-up, Community Advisory Board (CAB) support for meetings, protocol updates and reporting, attendance and participation in site monitoring visits, attendance at the annual network meeting, invoicing and other report preparation.
  25. Experience coordinating data from all aspects of ongoing protocols, studies, and trials.
  26. Experience in initiating and managing 3-6 studies each year.
  27. Experience initiating and managing studies of different sizes from approximately 100 participants up to approximately 10,000 participants.
  28. Experience working with populations experiencing health disparities, e.g., people in low socioeconomic conditions, living in rural underserved areas, and racial and/or ethnic populations who have documented health disparities based on diseases and conditions.
  29. Experience initiating and managing studies with a length in time from a few months for cross-sectional studies to a few years in clinical studies.
  30. Experience managing studies of varying complexities from simpler studies, which may be qualitative studies involving in-depth interviews with about 100 people; to more complex studies that involve a multi-site clinical trial with 1-2 years follow-up including biospecimen collection.


Commercial Availability of Services – Based on preliminary market research, the Government anticipates that the contemplated research services may be noncommercial in nature. However, interested respondents are encouraged to identify comparable services available in the commercial marketplace. If so, describe which portions of the requirement could be met commercially and which would require customization, integration, or specialized development. Provide supporting information, including customary pricing practices and potential firm-fixed-price arrangements, if available.


Industry Feedback on Draft SOW – Respondents are encouraged to provide comments or recommendations on the draft SOW, including opportunities to clarify requirements, improve performance outcomes, identify potential implementation challenges, or incorporate commercially available approaches. Identify any provisions that may unnecessarily limit small business participation and suggest practical alternatives. Any recommendations should identify the applicable SOW section when possible.



Anticipated Award Date:


The Government expects to award an Indefinite Delivery Indefinite Quantity (IDIQ) contract approximately in September 2027.


Disclaimer and Important Notes: This notice does not obligate the government to award a contract or otherwise pay for the information provided in response. The Government reserves the right to use information provided by respondents for any purpose deemed necessary and legally appropriate. Any organization responding to this notice should ensure that its response is complete and sufficiently detailed to allow the Government to determine the organization’s qualifications to perform the work. Respondents are advised that the Government is under no obligation to acknowledge receipt of the information received or provide feedback to respondents with respect to any information submitted. After a review of the responses received, a presolicitation synopsis and solicitation may be published in SAM.gov. However, responses to this notice will not be considered adequate responses to a solicitation. No award will be made as a result of this notice. The Government will NOT be responsible for any costs incurred by the respondents to this Notice. This notice is for information purposes only.


CONFIDENTIALITY: No proprietary, classified, confidential, or sensitive information should be included in your response. The government reserves the right to use any nonproprietary technical information in any resultant solicitation(s).


Responses and Capability Statements:


Interested Small Businesses that believe they possess the capabilities necessary to undertake this project should submit an electronic copy of their capability statement addressing the areas listed above to the attention of Edwin Osorio, Contract Specialist (E-mail: contact@example.gov) and Lisa Schaupp, Contracting Officer (E-mail: contact@example.gov).


Please state clearly in the subject line of the email that it is in response to the Sources Sought notice no.75N94027R00005. Please limit responses to 20 pages or less, exclusive of resumes. Electronic capability statements should be received by the Contracting Officer and Contract Specialist by 4:30 PM Eastern time on November 25, 2026. Respondents must submit their capability statement via electronic submission only. Capability statements must identify the 1) organization name, address, point of contact, contact phone number, and email address; 2) Small Business status of the organization, NAICS code along with SAM.gov Unique Entity Identifier (UEI) and CAGE code, if assigned, size and type of business (e.g., 8(a), HUBZone, etc.). No phone calls will be accepted. The designated NAICS code for this effort is 541715 and the size standard is 1,000 employees or less.


Respondents may provide brief SOW comments and commercial availability information within the existing 20-page response limit. The Government may use the information received to refine the draft SOW and acquisition strategy; participation does not preclude responding to any future solicitation.

Similar Contracts

Same NAICS industry code

NAICS: 541715
New
Federal
Area of Interest: OSW Cost Assessment and Program Evaluation (CAPE) Modeling and Simulation
Solicitation # HQ003427AOI5
The Washington Headquarters Services is soliciting innovative commercial solutions under solicitation HQ003427AOI05 to establish a next-generation modeling and simulation architecture for the Office of the Secretary of War Cost Assessment and Program Evaluation. The objective is to replace legacy infrastructure with a unified computational backbone that compresses the cycle time between budget queries and warfighting insights. This architecture must integrate three functional layers: a high-performance simulation execution layer for large-scale model runs, a machine-learned surrogate emulation layer for hosting government-developed models, and an intuitive self-service quantitative analysis layer for visualization and sensitivity analysis. The technical requirements specify a high-performance compute environment capable of executing between 1,200 simulations in 10 hours for light cases and up to 150,000 simulations within two weeks for heavy cases. The system must operate at Impact Level 6, support network throughput between 100 Mbps and 1 Gbps, and be accessible from the Pentagon and Mark Center. It must accommodate a diverse software ecosystem including Python, R, Java, PyTorch, and large language models. While the government will retain exclusive operational tenant administration and control over data and security permissions, the commercial provider will be responsible for turnkey managed IT operations, including hardware availability, patching, and cybersecurity hardening. Interested respondents must submit white papers by November 12, 2026, in accordance with Commercial Solutions Opening procedures.
Washington Headquarters Services

POSTED

about 12 hours ago

DEADLINE

in 6 days
View Details
NAICS: 541715
New
Federal
Space Data Network (SDN) Industry Consortium for Space-to-Space Communications
Solicitation # SDN-CONSORT-27-01
The Space Systems Command’s Space Data Network Backbone (SDN-B) program office is establishing the Space Data Network (SDN) Industry Consortium to develop a proliferated, vendor-diverse space-to-space communications mesh in Low Earth Orbit (LEO). This initiative seeks to create a public-private partnership to solve technical integration and architectural challenges, specifically focusing on domains such as Optical Inter-Satellite Links (OISL), RF mesh communications, space networking and routing, and cybersecurity. Selected industry members will join as Associate Members under a $0-value Other Transaction Agreement (OTA) pursuant to 10 U.S.C. § 4022, participating in technical working groups and interoperability assessments. Membership is strictly limited to U.S.-owned and operated entities with active SAM.gov registrations under NAICS 541715. Applicants must demonstrate the ability to handle Controlled Unclassified Information (CUI) in compliance with NIST SP 800-171 and DoD CMMC standards, though higher security clearances are welcomed. To be considered, respondents must submit a package by November 23, 2026, consisting of a one-page cover sheet and a maximum two-page white paper detailing their technical contribution and alignment with the SDN architecture. Onboarding decisions will be based on technical relevance, commercial maturity, and the vendor's willingness to collaborate on multi-vendor standards.
FA8819 Sda And Combat Power Szk-La

POSTED

about 12 hours ago

DEADLINE

in 13 days
View Details
NAICS: 541715
New
Federal
Prototype development for Battlefield Wound Infection Prevention and Treatment (BWI P&T) Barrier Combination
Solicitation # HT9427-26-R-E020
The Defense Health Agency Contracting Activity is seeking a single award for the development of a Battlefield Wound Infection Prevention and Treatment Barrier Combination prototype. This medical product must integrate a physical wound barrier with antimicrobial and antifungal properties to prevent systemic infections in combat scenarios. The project is being executed under prototype Other Transaction Authority 10 U.S.C. 4022, meaning it does not follow standard FAR-based procurement. The goal is to advance the technology from a preferred starting point of Technology Readiness Level 5 to TRL 7 at the time of FDA submission, and TRL 8 upon final FDA approval or clearance. The scope of work includes preclinical testing, human clinical trials, and the submission of regulatory packages for FDA approval. Key deliverables include a working prototype of 50 units, a quality management plan, and comprehensive technical documentation. The final product must be compact, waterproof, and capable of being opened with one hand in low-light environments, while maintaining stability in temperatures ranging from 0 to 110 degrees Fahrenheit. Proposals are due by November 20, 2026, and must be submitted in three separate volumes covering technical, management, and administrative/cost details. The government prefers a Firm Fixed Price agreement but will consider Cost Plus Fixed Fee structures.
Defense Health Agency

POSTED

about 12 hours ago

DEADLINE

in 10 days
View Details
NAICS: 541715
New
Federal
UAS BROAD AGENCY ANNOUNCEMENT Solicitation Number: 697DCK-25-R-00278 Call 002-2027
Solicitation # 697DCK-25-R-00278
Solicitation number 697DCK-25-R-00278 is a Broad Agency Announcement issued by the Federal Aviation Administration Unmanned Aircraft Systems Integration Office to support the safe integration of Unmanned Aircraft Systems into the National Airspace System. Open through September 30, 2028, the BAA focuses on five key areas: UAS Traffic Management, Beyond-Visual-Line-of-Sight operations, industry consensus standards, electronic conspicuity, and noise and environmental impacts. The procurement utilizes a two-step process where interested parties first submit a whitepaper for preliminary consideration, and selected respondents are subsequently issued a Request for Proposal. Under Call 001A-2026, whitepapers must be submitted by April 9, 2026, and must include a Letter of Attestation from an FAA UAS Test Site, with a specific requirement for projects to partner with either the Indiana Economic Development Corporation or the Choctaw Nation of Oklahoma Emerging Aviation Technology Center. Awards are structured as cost-reimbursement contracts with no fee, requiring a minimum 1:1 cost-share where the FAA pays no more than 50 percent of the total project cost. Evaluation is based on operational readiness, mission importance, and funding availability, with a strong preference for technologies already demonstrated in an operational environment.
697DCK Regional Acquisitions Svcs

POSTED

about 12 hours ago

DEADLINE

in almost 2 years
View Details

More opportunities from Department Of Health And Human Services → National Institutes Of Health Olao

Same awarding agency

NAICS: 541990
New
Federal
NIH Scientific & Technical Expertise & Acquisition Management (STEAM)
Solicitation # 75N98027R00012
The National Institutes of Health (NIH) is conducting market research through a Sources Sought Notice for the Scientific and Technical Expertise Acquisition and Management (STEAM) program. This initiative aims to secure professional, scientific, and technical contractor support to advance biomedical and behavioral research. The program is structured into two primary task areas: Task Area A, which covers general professional, management, administrative, and IT support, and Task Area B, which focuses on highly specialized scientific services, including research and development, laboratory services, and clinical or animal-care roles. To be considered capable, respondents must demonstrate the ability to fill every labor category within their chosen task area; partial capability is insufficient. The program requires a high degree of specialization, particularly for Task Area B, which necessitates support for Biosafety Level (BSL) 1 through 4 and Animal Biosafety Level (ABSL) 1 through 4 environments. The anticipated period of performance is a five-year ordering period from April 2027 through April 2032. Services will be delivered via project-based task orders, with some requiring urgent mobilization within 48 hours. The government is specifically seeking information from small businesses regarding their socioeconomic status, capacity to manage a substantial volume of concurrent projects, and ability to handle cost-reimbursement contracting. Primary performance locations include Bethesda and Rockville, Maryland, the Washington DC metropolitan area, and Hamilton, Montana.
All Other Professional, Scientific, and Technical Services

POSTED

about 12 hours ago

DEADLINE

in 6 days
View Details
NAICS: 325413
New
Federal
Reagents and consumables for Roche immunostainers
Solicitation # 75N98027Q00026
Solicitation 75N98027Q00026 is a Firm-Fixed-Price Indefinite Delivery Indefinite Quantity (IDIQ) contract issued by the National Institutes of Health Office of Logistics and Operations. The objective is to procure proprietary reagents, kits, and consumables compatible with the National Cancer Institute's Roche Ventana Benchmark ULTRA and Benchmark Plus immunostainers. The contract includes a base year starting December 1, 2026, with four subsequent option years, carrying a minimum value of 20,000 dollars and a maximum value of 1.5 million dollars. The scope of work extends beyond supplies to include no-cost software upgrades, VConnect software coverage, and professional consultation from scientists and engineers. The contractor must adhere to strict quality and delivery standards, including overnight shipping using industry-best practices such as dry or wet ice, and ensuring all reagents have expiration dates exceeding 12 months from the shipping date. Deliveries are f.o.b. destination to Bethesda, Maryland, and must typically be completed within five days of a task order. Award will be based on a best value tradeoff evaluation considering technical proposal, equipment capability, delivery, and price. Offerors must provide a Unique Entity Identifier, Taxpayer Identification Number, and business size certification, with responses due by November 16, 2026.
In-Vitro Diagnostic Substance Manufacturing

POSTED

about 12 hours ago

DEADLINE

in 8 days
View Details

Ready to Pursue This Opportunity?

Get AI-powered intelligence on this solicitation and the ones like it

Every page of the solicitation package shredded into a compliance breakdown

AI-powered matching based on your capabilities and past performance

Competitor and incumbent history on the requirement

Automated alerts on amendments, Q&A deadlines, and award

Miguel
Hillary
Keith Deutsch
Christine

Join 750+ contractors already using CLEATUS